From candidate to default: the company has just been placed inside buyers' own purchasing systems
The model's full reasoning — Q4 2021 call → NOWe need to determine if management describes a recent transition to being an approved/specified/listed/etc. choice inside buyers' systems, such that future business can arrive without discrete selling events, and that this is new enough that most volume is ahead. Scan the transcript for such descriptions. Key points: partnerships, customer wins, HRD solution, AstraZeneca partnership, Ambry Genetics, GE Healthcare, etc. But are these "approved supplier" or "formulary" type statuses? The question asks about being inside buyers' purchasing/reimbursement/specification systems. The transcript mentions partnerships and collaborations, but not explicitly that the company is now a specified/approved vendor in a routine pathway. It mentions "land and expand" and customer adoption, but that's standard selling. There's no mention of being added to a formulary, approved vendor list, or similar. The AstraZeneca partnership is about expanding access to HRD testing, but it's a collaboration, not necessarily a listing in a procurement system. The Ambry Genetics LOI is a partnership, not a qualification. The GE partnership is about integration, not a buyer-side system. No mention of reimbursement codes, payer networks, etc. The company is a software platform, and customers are hospitals/labs. The transcript does not describe a recent transition to a default status. It describes ongoing customer wins and partnerships. So answer NO. But let's double-check: The question asks if management conveys that the company has recently crossed into being an approved/specified/listed choice. The transcript mentions "we are expecting several signed agreements with Tier 1 institutions" and "we recently announced onboarding" etc. That's just customer wins. No mention of being placed on a list. The HRD solution with AstraZeneca is a partnership to expand access, but not a listing. The "DEEP-Lung-IV" study is a clinical study, not a procurement pathway. So no. Thus answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| INGN | Inogen, Inc. | Q1 2023 | 2023-05-05 | F |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| MGNI | Magnite, Inc. | Q1 2022 | 2022-05-04 | D |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
PRIM · Q2 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this shift for the newly acquired T&D segment: after the Willbros acquisition (closed June 1, 2018), the T&D Group gained access to major utilities that had been hesitant due to prior financial concerns. With Primoris as parent, they signed new awards from the 3 largest electrical utilities (one announced MSA, two not yet announced), allowing work to flow under existing relationships without repeated persuasion. Management explicitly ties this to the recent acquisition and notes the MSA backlog now at $1.1 billion (first time exceeding $1 billion), with one-year estimated MSA revenue at $1.1 billion and continued growth expected.
AGIO · Q3 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this transition for TIBSOVO. Steve Hoerter states that the company launched in July 2018 and is now receiving reimbursement with “no payer-related coverage issues,” with the payer mix (60% Medicare, 35% commercial) reflecting routine placement in those systems. He further notes that initial prescriptions are being written by over 100 unique prescribers and that awareness is already above 90%, confirming the product has moved from candidate status into the reimbursement and purchasing pathways. Because the launch is only a few months old at the time of the call, the $4.
AZEK · Q2 2024 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, etc...YES The transcript shows management describing recent and incremental shelf-space gains in both pro and retail channels as a new development that will support growth in 2025, with investments planned for Q4 to enable these gains. This is framed as moving beyond prior years' steady execution into fresh wins that create a tailwind for future 2025 volume, where the company is now positioned to benefit from expanded availability in buyer systems (catalogs, dealer networks, and retail displays) without needing to re-persuade for each order.